Compare CHMG & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CHMG | AKBA |
|---|---|---|
| Founded | 1833 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 398.6M | 343.4M |
| IPO Year | 1995 | 2014 |
| Metric | CHMG | AKBA |
|---|---|---|
| Price | $84.46 | $0.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $57.00 | $4.67 |
| AVG Volume (30 Days) | 36.9K | ★ 8.7M |
| Earning Date | 04-17-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | N/A | ★ 93.94 |
| EPS | ★ 3.73 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $37.32 | N/A |
| Revenue Next Year | $9.13 | N/A |
| P/E Ratio | $22.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $49.82 | $0.81 |
| 52 Week High | $86.00 | $3.19 |
| Indicator | CHMG | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 62.64 | 41.57 |
| Support Level | $80.16 | $0.84 |
| Resistance Level | N/A | $0.96 |
| Average True Range (ATR) | 1.83 | 0.07 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 87.64 | 24.74 |
Chemung Financial Corp is a bank holding firm. Through its subsidiaries, the company provides various financial services, including demand, savings, and time deposits, commercial, residential, and consumer loans, letters of credit, wealth management services, employee benefit plans, insurance products, mutual funds, and brokerage services, among others. The company's reportable segments are Core Banking, Wealth Management (WMG) services, and Holding company and CFS. Maximum revenue is generated from the Core Banking segment, which derives revenue by attracting deposits from the general public and using such funds to originate different types of loans, and to invest in securities. The Wealth Management (WMG) services segment provides trust and investment advisory services to clients.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.